
Annual report 2025
added 03-13-2026
Aziyo Biologics Revenue 2011-2026 | AZYO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aziyo Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.3 M | 14.5 M | 24.7 M | 23.8 M | 47.4 M | 42.7 M | 42.9 M | 39 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.4 M | 12.3 M | 30.9 M |
Quarterly Revenue Aziyo Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.32 M | 6.26 M | 6.03 M | 3.66 M | 6.29 M | 6.69 M | 6.13 M | 6.35 M | 6.39 M | - | 5.85 M | 12.6 M | 11.5 M | - | 11.5 M | 12.2 M | 12.9 M | - | 11.8 M | 8.58 M | 9.86 M | - | 11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 M | 3.32 M | 8.37 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
764 M | $ 11.02 | 1.06 % | $ 1.65 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.6 | -1.66 % | $ 37.3 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.36 | 1.25 % | $ 1.49 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.32 | 0.61 % | $ 124 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.87 | -1.05 % | $ 1.14 M | ||
|
Align Technology
ALGN
|
4 B | $ 173.99 | 0.49 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.21 | 0.33 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.02 | 2.01 % | $ 17.3 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 282.96 | 1.33 % | $ 7.98 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.02 | 1.14 % | $ 5.66 K | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.08 | 0.47 % | $ 91.9 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 62.79 | 0.02 % | $ 3.43 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.88 | 3.16 % | $ 70.3 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.12 | 5.07 % | $ 258 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
64 M | $ 24.2 | 0.33 % | $ 205 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Inogen
INGN
|
349 M | $ 6.49 | 2.53 % | $ 173 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.42 | 2.82 % | $ 385 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.13 | 0.79 % | $ 12.3 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.8 | 4.48 % | $ 7.77 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.1 | -0.24 % | $ 868 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 340.42 | 0.37 % | $ 130 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.22 | 1.79 % | $ 366 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.57 | 0.46 % | $ 26.8 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.69 | 0.06 % | $ 28.9 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.12 | 0.19 % | $ 1.59 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.88 | 0.38 % | $ 1.14 B |